163 related articles for article (PubMed ID: 8357970)
1. Epidermal Langerhans cells and prognosis of patients with mycosis fungoides and Sezary syndrome.
Meissner K; Löning T; Rehpenning W
In Vivo; 1993; 7(3):277-80. PubMed ID: 8357970
[TBL] [Abstract][Full Text] [Related]
2. Epidermal Langerhans' cell densities influence survival in mycosis fungoides and Sézary syndrome.
Meissner K; Michaelis K; Rehpenning W; Löning T
Cancer; 1990 May; 65(9):2069-73. PubMed ID: 2196990
[TBL] [Abstract][Full Text] [Related]
3. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
Meissner K; Löning T; Rehpenning W
Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
6. Epidermal Langerhans cells in mycosis fungoides and Sézary syndrome.
Matejka M; Konrad K
Wien Klin Wochenschr; 1983 Dec; 95(23):847-52. PubMed ID: 6670281
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
8. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
Suzuki SY; Ito K; Ito M; Kawai K
J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
[TBL] [Abstract][Full Text] [Related]
10. Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome.
Hristov AC; Vonderheid EC; Borowitz MJ
Am J Clin Pathol; 2011 Dec; 136(6):944-53. PubMed ID: 22095381
[TBL] [Abstract][Full Text] [Related]
11. Mycosis fungoides/Sézary syndrome: report of an unusual case.
Mehta A; Dhungel BM; Khan MF
J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome.
Bi MY; Curry JL; Christiano AM; Hordinsky MK; Norris DA; Price VH; Duvic M
J Am Acad Dermatol; 2011 Jan; 64(1):53-63. PubMed ID: 21036417
[TBL] [Abstract][Full Text] [Related]
13. Total skin electron beam therapy in mycosis fungoides. Our experience from 1985 to 1999.
Rampino M; Ragona R; Monetti U; Mussano A; Guarneri A; Sannazzari GL
Radiol Med; 2002; 103(1-2):108-14. PubMed ID: 11859306
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical studies using monoclonal antibodies on lymph nodes from patients with mycosis fungoides and Sézary's syndrome.
Willemze R; Scheffer E; Meijer CJ
Am J Pathol; 1985 Jul; 120(1):46-54. PubMed ID: 3893151
[TBL] [Abstract][Full Text] [Related]
15. [Clinicomorphological characteristics of Sezary's disease and mycosis fungoides].
Vinogradova IuE; Giliazitdinova EA; Zamulaeva IA; Zybunova EE; Kaplanskaia IB; Kravchenko SK; Kremenetskaia AM; Lutsenko IN; Samoĭlova RS; Selivanova EN; Sidorova IuV; Shklovskiĭ-Kord NE
Ter Arkh; 2005; 77(10):61-5. PubMed ID: 16320688
[TBL] [Abstract][Full Text] [Related]
16. Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions.
Doherty SD; Ni X; Doherty CB; Jones D; Zhao X; Owen LB; Duvic M
Arch Dermatol Res; 2006 Dec; 298(7):353-6. PubMed ID: 17021762
[TBL] [Abstract][Full Text] [Related]
17. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
[TBL] [Abstract][Full Text] [Related]
18. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
19. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
20. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]